These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34169667)

  • 1. Modification of MRI pattern of high-grade glioma pseudoprogression in regorafenib therapy.
    Mansour M; Vitale V; Lombardi G; Riva G; Pancheri F; Zanusso M
    J Med Imaging Radiat Oncol; 2022 Apr; 66(3):414-418. PubMed ID: 34169667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
    Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
    Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression.
    Shi W; Qu C; Wang X; Liang X; Tan Y; Zhang H
    Eur J Radiol; 2021 Nov; 144():109941. PubMed ID: 34735828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
    Grabner G; Kiesel B; Wöhrer A; Millesi M; Wurzer A; Göd S; Mallouhi A; Knosp E; Marosi C; Trattnig S; Wolfsberger S; Preusser M; Widhalm G
    Eur Radiol; 2017 Apr; 27(4):1556-1567. PubMed ID: 27300198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
    Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
    Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
    Prager AJ; Martinez N; Beal K; Omuro A; Zhang Z; Young RJ
    AJNR Am J Neuroradiol; 2015 May; 36(5):877-85. PubMed ID: 25593202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
    Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
    AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
    Nierobisch N; Ludovichetti R; Kadali K; Fierstra J; Hüllner M; Michels L; Achangwa NR; Alcaide-Leon P; Weller M; Kulcsar Z; Hainc N
    Eur J Radiol; 2023 Oct; 167():111076. PubMed ID: 37666072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric magnetic resonance imaging features of giant intracranial tuberculomas.
    Peer S; Tiwari S; Swaminathan AD; Jabeen S; Saini J; Prasad C; Kulanthaivelu K; Murumkar V; Vengalil S; Netravathi M; Nalini A; Raju S; Swaroop NS; Srinivas D
    Clin Neurol Neurosurg; 2021 Nov; 210():107006. PubMed ID: 34739879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib in patients with recurrent high-grade astrocytoma.
    Kebir S; Rauschenbach L; Radbruch A; Lazaridis L; Schmidt T; Stoppek AK; Pierscianek D; Stuschke M; Forsting M; Sure U; Keyvani K; Kleinschnitz C; Scheffler B; Glas M
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1037-1042. PubMed ID: 30820715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma patients.
    Kim TH; Yun TJ; Park CK; Kim TM; Kim JH; Sohn CH; Won JK; Park SH; Kim IH; Choi SH
    Oncotarget; 2017 Mar; 8(12):20340-20353. PubMed ID: 27823971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
    Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
    AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative Grading of Glioma Using Dynamic Susceptibility Contrast MRI: Relative Cerebral Blood Volume Analysis of Intra-tumoural and Peri-tumoural Tissue.
    Soliman RK; Gamal SA; Essa AA; Othman MH
    Clin Neurol Neurosurg; 2018 Apr; 167():86-92. PubMed ID: 29471287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.